The researches find that the It can be difficult to treat malignant tumors using radical particle therapy if the tumor is too close to healthy organs. A team led by Professor Takumi Fukumoto and Professor Ryohei Sasaki; (Kobe University Graduate School of Medicine); has collaborated with Alfresa Pharma Corporation to develop a new medical device “Neskeep” to separate tumors from adjacent normal organs during particle therapy. The Neskeep is designed to be placed by surgical procedure.
Using radical particle therapy
Neskeep received pharmaceutical approval in December 2018 and is available to purchase from June 27, 2019. Radiation therapy; which is one of the less invasive and less stressful treatments; has been recognize as an important cancer treatment. Health insurance from the Japanese government covers particle therapies for bone and soft tissue tumors; pediatric malignant tumors; and non-squamous head and neck tumors.
In some cases, it can be difficult to apply particle therapy when malignant tumors are located near digestive tract organs sensitive to radiation (the small and large intestine). Doctors currently use non-absorbent materials such as silicone balloons and Gore-Tex sheets to act as spacers in the abdomen and intestines; or they place the intestine or other organs outside the radiation field using an absorbent mesh. Based on several observations; some patients may then undergo a second surgery to remove the spacer or it may cause serious complications in their bodies for the rest of their lives.
The abdomen and intestines
The team succeeded in developing a nonwoven fabric bioabsorbable spacer that can create a space between healthy and cancerous tissues during particle therapy. After that the spacer is safely absorb by the body. In their preclinical evaluation; the team conducted physical experiments to check that the spacer fulfilled the requirements for isolating cancer from organs and providing a barrier against radiation. After safety studies in animal models; a clinical trial is carry out in Kobe University Hospital and Hyogo Ion Beam Medical Center (HIBMC).
The human trial involved five patients with malignant tumors in the abdominal or pelvic region; for whom particle therapy was difficult because of the proximity of normal organs to the cancer. In all treatments the spacer preserved enough distance between the tumor and healthy tissue during the particle therapy. But Having successfully reduced the radiation exposure to the intestines; they were able to use a full dose of radiation therapy. There were no serious complications observed with this treatment, and they confirmed that the spacers safely disintegrated afterwards.